2023
Evolution of predictive risk factor analysis for chemotherapy-related toxicity
Hertz D, Lustberg M, Sonis S. Evolution of predictive risk factor analysis for chemotherapy-related toxicity. Supportive Care In Cancer 2023, 31: 601. PMID: 37773300, DOI: 10.1007/s00520-023-08074-x.Peer-Reviewed Original ResearchConceptsTreatment-related toxicityBiomarker discovery approachClinical practiceTaxane-induced peripheral neuropathyChemotherapy-related toxicitySame treatment regimenMaximum treatment benefitRisk factor analysisPrecision oncology treatmentsToxicity riskPeripheral neuropathyTreatment regimenSimilar patientsToxicity predictorsTreatment benefitPharmacogenetic predictorsOncology treatmentSide effectsTherapeutic outcomesCancer treatmentMinimal toxicityIntegrated biomarkersGermline genomicsBiomarker sciencePatients
2021
Genomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cellsTriple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Review Of Anticancer Therapy 2021, 21: 135-148. PMID: 33198517, PMCID: PMC8174647, DOI: 10.1080/14737140.2021.1840984.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorFemaleHumansMolecular Targeted TherapyPrognosisSurvival RateTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerHuman epidermal growth factor receptor 2Vascular endothelial growth factorHomologous recombination deficiencyBreast cancerEpidermal growth factor receptorGrowth factor receptorPredictive biomarkersTreatment optionsFibroblast growth factor receptorManagement of TNBCEpidermal growth factor receptor 2Factor receptorGrowth factor receptor 2PI3K/Akt/mTORLimited treatment optionsNTRK gene fusionsFactor receptor 2Akt/mTOREndothelial growth factorCell-free DNAAntibody-drug conjugatesClinical outcomesImmune biomarkersPoor prognosis
2018
PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer
Hou Y, Nitta H, Wei L, Banks P, Lustberg M, Wesolowski R, Ramaswamy B, Parwani A, Li Z. PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer. The Breast Journal 2018, 24: 911-919. PMID: 30230111, PMCID: PMC6724200, DOI: 10.1111/tbj.13112.Peer-Reviewed Original ResearchConceptsPD-L1 expressionCD8-positive T cellsTumor-infiltrating lymphocytesHER2-positive casesLymph node metastasisCytotoxic immune reactionsBreast carcinomaImmune reactionsNode metastasisPD-L1Immune cellsConventional chemotherapyBreast cancerT cellsTissue microarrayHER2-positive invasive breast cancerHER2-positive invasive breast carcinomasHER2-positive breast cancerHER2-positive breast carcinomasTumor cellsPD1/PD-L1 expressionHigh Nottingham gradePD-L1 stainingInvasive breast cancerLower tumor stageImplementing Liquid Biopsies in Clinical Trials
Lustberg M, Stover D, Chalmers J. Implementing Liquid Biopsies in Clinical Trials. The Cancer Journal 2018, 24: 61-64. PMID: 29601331, PMCID: PMC5880324, DOI: 10.1097/ppo.0000000000000309.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorClinical Trials as TopicHumansLiquid BiopsyNeoplasmsPrecision MedicineConceptsClinical trialsLiquid biopsyReal-time biopsySurrogate efficacy endpointsTreatment response evaluationMultiple clinical trialsRoutine clinical practiceCell-free DNATumor-specific biomarkersEfficacy endpointBlood markersPredictive biomarkersPharmacodynamic biomarkersPrognostic biomarkerTreatment selectionTumor markersBiopsyClinical practiceDisease statusTumor cellsResponse evaluationAdditional studiesBiomarkersTrialsExtracellular vesicles
2017
Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples
Miller B, Lustberg M, Summers T, Chalmers J. Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples. Methods In Molecular Biology 2017, 1634: 219-234. PMID: 28819855, DOI: 10.1007/978-1-4939-7144-2_19.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCarbocyaninesCell CountCell Line, TumorEpithelial Cell Adhesion MoleculeFemaleFluorescent DyesHumansHydrazinesImage Processing, Computer-AssistedIndolesKeratinsLeukocyte Common AntigensLeukocytes, MononuclearLiquid CrystalsNeoplastic Cells, CirculatingOptical ImagingSoftwareSuccinimidesConceptsPeripheral blood samplesBlood samplesPeripheral bloodTumor cellsLiquid biopsyUseful predictive markerSolid tumor malignanciesVariety of disordersUndefined cell typesLow EpCAM expressionSpecific cell surface markersCell surface markersVariety of biomarkersPredictive markerTherapeutic responseSolid tumorsPositive selection technologyDisease statusTumor malignancyFuture validation studiesEpCAM expressionSurface markersMultispectral imaging analysisProtein levelsExact role
2015
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
Oliveira-Costa J, de Carvalho A, da Silveira G, Amaya P, Wu Y, Park K, Gigliola M, Lustberg M, Buim M, Ferreira E, Kowalski L, Chalmers J, Soares F, Carraro D, Ribeiro-Silva A. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015, 6: 20902-20920. PMID: 26041877, PMCID: PMC4673238, DOI: 10.18632/oncotarget.3939.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAutoimmune DiseasesB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellCohort StudiesCytoplasmDNA-Binding ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMouth NeoplasmsNeoplastic Cells, CirculatingOligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsTissue BanksTreatment OutcomeConceptsOral squamous cell carcinomaPD-L1Tumor sizePerineural invasionPrimary tumorAdvanced oral squamous cell carcinomaTumor cellsSquamous cell carcinoma developmentStrong cytoplasmatic expressionPD-L1 positivityDisease-specific survivalOral squamous cell carcinoma developmentPD-L1 expressionIndependent prognostic factorLymph node metastasisT cell activitySquamous cell carcinomaSub-classify patientsSpecific survivalNode metastasisPD-1Prognostic factorsPoor prognosisAutoimmune diseasesCell carcinoma
2014
Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients
Lustberg M, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae E, Wesolowski R, Layman R, Mrozek E, Pan X, Summers T, Shapiro C, Chalmers J. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Research 2014, 16: r23. PMID: 24602188, PMCID: PMC4053256, DOI: 10.1186/bcr3622.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesCell Line, TumorEpithelial Cell Adhesion MoleculeErbB ReceptorsFemaleFlow CytometryHumansImmunohistochemistryKeratin-18Keratin-19Keratin-8Leukocyte Common AntigensMCF-7 CellsMicroscopy, ConfocalMiddle AgedNeoplasm MetastasisNeoplastic Cells, CirculatingPrognosisProspective StudiesVimentinConceptsMetastatic breast cancerBreast cancer patientsBlood samplesCancer patientsBreast cancerMetastatic breast cancer patientsPatient samplesMultiparametric flow cytometry analysisAtypical cell populationNumber of CKPresent prospective trialWorse overall survivalTumor-associated macrophagesCell populationsPan-hematopoietic marker CD45Confocal microscopyEpidermal growth factor receptorEpithelial cell adhesion moleculeNormal control samplesCell surface markersRole of EpCAMFlow cytometry analysisGrowth factor receptorOverall survivalProspective trial
2013
Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology
Wu Y, Deighan C, Miller B, Balasubramanian P, Lustberg M, Zborowski M, Chalmers J. Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology. Methods 2013, 64: 169-182. PMID: 24056212, PMCID: PMC3874448, DOI: 10.1016/j.ymeth.2013.09.006.Peer-Reviewed Original ResearchConceptsCancer patientsMetastatic breast cancer patientsBreast cancer patientsPeripheral blood samplesRed blood cell lysisRare cellsNon-hematopoietic cellsBlood cell lysisImmunomagnetic depletionCD45 antibodyBlood samplesLog depletionPatientsImmunofluorescence stainingNucleated cellsWhole bloodBloodCD45RBC lysisCellsCell lysisLysisAntibodiesHuman Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival‐, apoptosis‐related molecules and microenvironment in tumors
Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg M, Ray A, Pompili V, Shapiro C, Das H. Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival‐, apoptosis‐related molecules and microenvironment in tumors. International Journal Of Cancer 2013, 133: 2133-2144. PMID: 23595559, PMCID: PMC3939063, DOI: 10.1002/ijc.28217.Peer-Reviewed Original ResearchConceptsΓδ T cellsVγ2Vδ2 T cellsT cellsApoptosis-related moleculesAntineoplastic effectsVγ2Vδ2 T-cell subsetTumor cellsInfiltration of tumorsMICA/BT cell subsetsHuman Vγ2Vδ2 T cellsBreast cancer growthExpression levelsInnate immune systemMolecular signalingBreast tumor cellsMDA-MB-231Resistant cell linesCell subsetsSurface expression levelsCancer growthImmune systemTumor growthMalignant transformationTumor progression
2012
Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck
Balasubramanian P, Lang J, Jatana K, Miller B, Ozer E, Old M, Schuller D, Agrawal A, Teknos T, Summers T, Lustberg M, Zborowski M, Chalmers J. Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck. PLOS ONE 2012, 7: e42048. PMID: 22844540, PMCID: PMC3406036, DOI: 10.1371/journal.pone.0042048.Peer-Reviewed Original ResearchConceptsEpithelial surface markersN-cadherinEpidermal growth factor receptorGrowth factor receptorSurface markersPositive selection approachEpithelial markersAforementioned proteinsMesenchymal transitionFactor receptorConfocal microscopyCancer metastasisEMT processCancer cellsPhenotypic patternsMesenchymal markersTumor metastasisEnrichment methodologyEMT markersEnrichment technologyCellsEMTExpressionTumor cellsMarkers